The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma

BACKGROUND: When considering optimal second-line treatments for metastatic renal cell carcinoma (mRCC), clinicians and payers seek to understand the relative clinical benefits and costs of treatment. OBJECTIVE: To use an economic model to compare the additional cost per month of overall survival (OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Swallow, Elyse, Messali, Andrew, Ghate, Sameer, McDonald, Evangeline, Duchesneau, Emilie, Perez, Jose Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398246/
https://www.ncbi.nlm.nih.gov/pubmed/29578848
http://dx.doi.org/10.18553/jmcp.2018.24.4.335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398246/
https://www.ncbi.nlm.nih.gov/pubmed/29578848
http://dx.doi.org/10.18553/jmcp.2018.24.4.335

Ejemplares similares